Shots:

• The approval is based on P-III EXPAND study assessing Mayzent vs PBO in 1651 patients with SPMS from 31 countries including 47 participants in Canada with a mean age of 48yrs.- living with MS for ~16yrs.- >50% had a median EDDS score of 6.0 and relied on a walking aid
• The P-III EXPAND study result demonstrated a reduction in diseases progression- including impact on physical disability
• Mayzent is an S1P receptor modulator and the first oral therapy approved for SPMS with active disease. The approval of Mayzent is a tribute to Novartis’s relentless commitment to reimagining MS treatment

Click here ­to­ read full press release/ article | Ref: Novartis | Image: StraitTimes